Medicines

Hero Banner. LEQVIO® (inclisiran) logo.
Hero Banner. LEQVIO® (inclisiran) logo.

Prescribing information

All images are of fictional patients and healthcare practitioners

LEQVIO® (inclisiran) is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:1

  • in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, or

  • alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated

For full safety information, please refer to the LEQVIO® Summary of Product Characteristics.

LEQVIO® (inclisiran)

Graphic with icons of 4 people, with one highlighted to illustrate that CVD accounts for over 1 in 4 deaths in Ireland.

CVD is one of the leading causes of death in Ireland, accounting for over a quarter (26.5%) of all deaths2

Despite current therapies to lower LDL-C, up to 80% of high-risk patients are unable to reach guideline indicated LDL-C levels.3

Square with the text ~50%.

On average, LDL-C levels were reduced by ~50% from baseline 
(2.92 ±1.2 mmol/L) in eligible patients with ASCVD on LEQVIO® and a maximally tolerated statin in an observational study, which is consistent with the placebo-corrected results seen in the Phase III trials ORION-9, ORION-10 and ORION-114–7

Icon of a shield.

In clinical trials, LEQVIO® had a safety profile similar to placebo, apart from injection-site reactions (8.2% and 1.8% of patients, respectively)1

ASCVD, atherosclerotic cardiovascular disease; LDL-C, low-density lipoprotein cholesterol.

References

  1. LEQVIO® Summary of Product Characteristics. Available at: www.medicines.ie.

  2. Central Statistics Office. Vital Statistics Yearly Summary 2021. Available at: https://www.cso.ie/en/releasesandpublications/ep/p-vsys/vitalstatisticsyearlysummary2021/ [Accessed April 2026].

  3. Offiah G, et al.  Ir J Med Sci 2022;192:1077–1084.

  4. Wright RS, et al. Oral presentation. European Society of Cardiology Congress. 25–28 August 2023, Amsterdam, The Netherlands.

  5. Raal FJ, et al. N Engl J Med 2020;382:1520–1530.

  6. Ray KK, et al. N Engl J Med 2020;382:1507–1519.

  7. Ray KK, et al. Eur Heart J 2022;43(48):5047–5057.

LEQVIO® and the LEQVIO® logo are registered trademarks of Novartis AG. Licensed from Alnylam Pharmaceuticals, Inc.

IE11496825-1 | April 2026

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk profile of the medicinal product. All suspected adverse reactions should be reported to HPRA Pharmacovigilance at www.hpra.ie. Adverse events can also be reported to Novartis preferably at www.novartis.com/report, by emailing [email protected] or by calling (01) 2080 612.